The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Rivaroxaban Market Research Report 2025
Synopsis
Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
The global Rivaroxaban market was valued at US$ 7995 million in 2023 and is anticipated to reach US$ 13970 million by 2030, witnessing a CAGR of 8.2% during the forecast period 2024-2030.
The major players in global Prom Dresses market include Bayer, Johnson and Johnson, etc. The top 2 players occupy nearly 100% of the market. Europe is the main market, and occupies nearly 100% of the global market. 10 mg is the main type, with a share over 30%. Venous Thromboembolism (VTE) is the main application, which holds a share about 85%.
This report aims to provide a comprehensive presentation of the global market for Rivaroxaban, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rivaroxaban.
Report Scope
The Rivaroxaban market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Rivaroxaban market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rivaroxaban manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer
J&J
Segment by Type
2.5 mg
10 mg
15 mg
20 mg
Segment by Application
Acute Coronary Syndrome (ACS)
Venous Thromboembolism (VTE)
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Rivaroxaban manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Rivaroxaban in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
The global Rivaroxaban market was valued at US$ 7995 million in 2023 and is anticipated to reach US$ 13970 million by 2030, witnessing a CAGR of 8.2% during the forecast period 2024-2030.
The major players in global Prom Dresses market include Bayer, Johnson and Johnson, etc. The top 2 players occupy nearly 100% of the market. Europe is the main market, and occupies nearly 100% of the global market. 10 mg is the main type, with a share over 30%. Venous Thromboembolism (VTE) is the main application, which holds a share about 85%.
This report aims to provide a comprehensive presentation of the global market for Rivaroxaban, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rivaroxaban.
Report Scope
The Rivaroxaban market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Rivaroxaban market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rivaroxaban manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer
J&J
Segment by Type
2.5 mg
10 mg
15 mg
20 mg
Segment by Application
Acute Coronary Syndrome (ACS)
Venous Thromboembolism (VTE)
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Rivaroxaban manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Rivaroxaban in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Rivaroxaban Market Overview
1.1 Product Overview and Scope of Rivaroxaban
1.2 Rivaroxaban Segment by Type
1.2.1 Global Rivaroxaban Market Value Comparison by Type (2024-2030)
1.2.2 2.5 mg
1.2.3 10 mg
1.2.4 15 mg
1.2.5 20 mg
1.3 Rivaroxaban Segment by Application
1.3.1 Global Rivaroxaban Market Value by Application: (2024-2030)
1.3.2 Acute Coronary Syndrome (ACS)
1.3.3 Venous Thromboembolism (VTE)
1.4 Global Rivaroxaban Market Size Estimates and Forecasts
1.4.1 Global Rivaroxaban Revenue 2019-2030
1.4.2 Global Rivaroxaban Sales 2019-2030
1.4.3 Global Rivaroxaban Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Rivaroxaban Market Competition by Manufacturers
2.1 Global Rivaroxaban Sales Market Share by Manufacturers (2019-2024)
2.2 Global Rivaroxaban Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Rivaroxaban Average Price by Manufacturers (2019-2024)
2.4 Global Rivaroxaban Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Rivaroxaban, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Rivaroxaban, Product Type & Application
2.7 Rivaroxaban Market Competitive Situation and Trends
2.7.1 Rivaroxaban Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Rivaroxaban Players Market Share by Revenue
2.7.3 Global Rivaroxaban Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Rivaroxaban Retrospective Market Scenario by Region
3.1 Global Rivaroxaban Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Rivaroxaban Global Rivaroxaban Sales by Region: 2019-2030
3.2.1 Global Rivaroxaban Sales by Region: 2019-2024
3.2.2 Global Rivaroxaban Sales by Region: 2025-2030
3.3 Global Rivaroxaban Global Rivaroxaban Revenue by Region: 2019-2030
3.3.1 Global Rivaroxaban Revenue by Region: 2019-2024
3.3.2 Global Rivaroxaban Revenue by Region: 2025-2030
3.4 North America Rivaroxaban Market Facts & Figures by Country
3.4.1 North America Rivaroxaban Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Rivaroxaban Sales by Country (2019-2030)
3.4.3 North America Rivaroxaban Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Rivaroxaban Market Facts & Figures by Country
3.5.1 Europe Rivaroxaban Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Rivaroxaban Sales by Country (2019-2030)
3.5.3 Europe Rivaroxaban Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Rivaroxaban Market Facts & Figures by Country
3.6.1 Asia Pacific Rivaroxaban Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Rivaroxaban Sales by Country (2019-2030)
3.6.3 Asia Pacific Rivaroxaban Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Rivaroxaban Market Facts & Figures by Country
3.7.1 Latin America Rivaroxaban Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Rivaroxaban Sales by Country (2019-2030)
3.7.3 Latin America Rivaroxaban Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Rivaroxaban Market Facts & Figures by Country
3.8.1 Middle East and Africa Rivaroxaban Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Rivaroxaban Sales by Country (2019-2030)
3.8.3 Middle East and Africa Rivaroxaban Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Rivaroxaban Sales by Type (2019-2030)
4.1.1 Global Rivaroxaban Sales by Type (2019-2024)
4.1.2 Global Rivaroxaban Sales by Type (2025-2030)
4.1.3 Global Rivaroxaban Sales Market Share by Type (2019-2030)
4.2 Global Rivaroxaban Revenue by Type (2019-2030)
4.2.1 Global Rivaroxaban Revenue by Type (2019-2024)
4.2.2 Global Rivaroxaban Revenue by Type (2025-2030)
4.2.3 Global Rivaroxaban Revenue Market Share by Type (2019-2030)
4.3 Global Rivaroxaban Price by Type (2019-2030)
5 Segment by Application
5.1 Global Rivaroxaban Sales by Application (2019-2030)
5.1.1 Global Rivaroxaban Sales by Application (2019-2024)
5.1.2 Global Rivaroxaban Sales by Application (2025-2030)
5.1.3 Global Rivaroxaban Sales Market Share by Application (2019-2030)
5.2 Global Rivaroxaban Revenue by Application (2019-2030)
5.2.1 Global Rivaroxaban Revenue by Application (2019-2024)
5.2.2 Global Rivaroxaban Revenue by Application (2025-2030)
5.2.3 Global Rivaroxaban Revenue Market Share by Application (2019-2030)
5.3 Global Rivaroxaban Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Corporation Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Rivaroxaban Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bayer Rivaroxaban Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 J&J
6.2.1 J&J Corporation Information
6.2.2 J&J Description and Business Overview
6.2.3 J&J Rivaroxaban Sales, Revenue and Gross Margin (2019-2024)
6.2.4 J&J Rivaroxaban Product Portfolio
6.2.5 J&J Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Rivaroxaban Industry Chain Analysis
7.2 Rivaroxaban Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Rivaroxaban Production Mode & Process
7.4 Rivaroxaban Sales and Marketing
7.4.1 Rivaroxaban Sales Channels
7.4.2 Rivaroxaban Distributors
7.5 Rivaroxaban Customers
8 Rivaroxaban Market Dynamics
8.1 Rivaroxaban Industry Trends
8.2 Rivaroxaban Market Drivers
8.3 Rivaroxaban Market Challenges
8.4 Rivaroxaban Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
